 MONT-SAINT-GUIBERT, Belgium, April 01, 2021 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that the company plans to participate at the following conferences in April 2021: 